### Metronidazole

**Indication**
Necrotising fasciitis  
**ICD11 code:** 1B71.Z

**INN**
Metronidazole

**Medicine type**
Chemical agent

**Antibiotic groups**
ACCESS

**List type**
Core

**Formulations**
- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Local > Rectal > Suppository: 1 g suppository (EML) ; 500 mg suppository (EML)
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Oral > Solid > tablet: 200 mg ; 250 mg ; 400 mg ; 500 mg

**EML status history**
- First added in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**
[Metronidazole](#)

**DrugBank**
[Metronidazole](#)

---

**Expert Committee recommendation**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- The addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.
- Replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc.
- The addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc.

---

**EML recommendations: Necrotising fasciitis**

<table>
<thead>
<tr>
<th>First choice</th>
<th>Second choice</th>
</tr>
</thead>
</table>
metronidazole
cooprescribed with ceftriaxone

cloxacillin
cooprescribed with piperacillin + tazobactam

tazobactam

tazobactam

tazobactam

tazobactam

tazobactam